Taysha (NASDAQ: TSHA) CEO gets 1,008,000 RSUs and 648,000 options
Rhea-AI Filing Summary
Taysha Gene Therapies, Inc. reported new equity awards to its Chief Executive Officer, Nolan Sean P. On January 12, 2026, he received 1,008,000 shares of common stock in the form of a restricted stock unit (RSU) award at a price of $0 per share, increasing his directly held common stock to 3,086,358 shares. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on his continued service.
On the same date, he was granted an employee stock option for 648,000 shares of common stock with an exercise price of $4.86 per share, expiring on January 12, 2036. Twenty-five percent of the option vests on January 12, 2027, with the remainder vesting in 36 equal monthly installments thereafter, also subject to continued service. Separately, 1,535,545 shares of common stock are held indirectly through Nolan Capital, LLC, where he has shared voting and investment power.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 648,000 | $0.00 | -- |
| Grant/Award | Common Stock | 1,008,000 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC. 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
